In early March 2011 the European College of Neuropsy-chopharmacology (ECNP) hosted a summit to consider the implications and consequences of the abrupt withdrawal of a number of major pharmaceutical companies from key areas of neuroscience research and development in brain disorders and psychopharmacology in particular. This paper presents the recommendations of the summit plus details of the background and analyses of the problem. It will be widely circulated within Europe and elsewhere.
展开▼
